Cargando…

Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma

Purpose/Objectives Combination BRAF (vemurafenib, dabrafenib, or encorafenib) plus MEK (trametinib, cobimetinib, or binimetinib) inhibitor therapy is now widely used in the treatment of metastatic melanoma. However, data for intracranial response to these drugs are limited. We aimed to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hui, Caressa, Wu, Yufan (Fred), Liu, Kevin, Sandhu, Navjot, Blomain, Erik, Binkley, Michael S, Gephart, Melanie H, Chang, Steven D., Li, Gordon H, Reddy, Sunil A, Soltys, Scott G, Pollom, Erqi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Radiation Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788920/ https://www.ncbi.nlm.nih.gov/pubmed/36579260 http://dx.doi.org/10.7759/cureus.31838

Ejemplares similares

Stereotactic Radiosurgery for Brain Metastases in Patients With a Heterozygous Germline Ataxia Telangiectasia Mutated Gene
por: Hall, Jennifer C, et al.
Publicado: (2023)

In Regard to Odei et al.
por: Kahn, Jenna M., et al.
Publicado: (2021)

Clinical impact of the VOLO optimizer on treatment plan quality and clinical treatment efficiency for CyberKnife
por: Schüler, Emil, et al.
Publicado: (2020)

Rectosigmoid Cancer—Rectal Cancer or Sigmoid Cancer?
por: Hui, Caressa, et al.
Publicado: (2022)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma
por: Khaddour, Karam, et al.
Publicado: (2021)

Stratified assessment of an FDA-cleared deep learning algorithm for automated detection and contouring of metastatic brain tumors in stereotactic radiosurgery
por: Wang, Jen-Yeu, et al.
Publicado: (2023)

Stereotactic Radiosurgery for Contrast-Enhancing Satellite Nodules in Recurrent Glioblastoma: A Rare Case Series From a Single Institution
por: Park, David J, et al.
Publicado: (2023)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
por: Sweetlove, Melanie, et al.
Publicado: (2015)

RADI-12. Deep learning for automatic detection and contouring of metastatic brain tumors in stereotactic radiosurgery: a retrospective analysis with an FDA-cleared software algorithm
por: Wang, Jen-Yeu, et al.
Publicado: (2021)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
por: Hamid, Omid, et al.
Publicado: (2019)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2021)

Evaluating Surgical Resection Extent and Adjuvant Therapy in the Management of Gliosarcoma
por: Jin, Michael C., et al.
Publicado: (2020)

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
por: Wang, Beike, et al.
Publicado: (2021)

Networking and Applying to Radiation Oncology During A Pandemic: Cross-Sectional Survey of Medical Student Concerns
por: Pollom, Erqi L., et al.
Publicado: (2021)

Intracranial Grade II Meningioma Oligometastatic to the Cervical Spine
por: Natarajan, Jyotsna M, et al.
Publicado: (2021)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
por: Stones, Clare J., et al.
Publicado: (2013)

Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma
por: Ryu, Sunhyo, et al.
Publicado: (2017)

A Predictive Model of Adaptive Resistance to BRAF/MEK Inhibitors in Melanoma
por: Ruiz, Emmanuelle M., et al.
Publicado: (2023)

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
por: Acciardo, Stefania, et al.
Publicado: (2018)

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
por: Gouda, M.A., et al.
Publicado: (2023)

Post-operative Stereotactic Radiosurgery of Malignant Melanotic Schwannoma
por: Hall, Jennifer C, et al.
Publicado: (2022)

Tumoral melanosis associated with combined BRAF/MEK inhibition (dabrafenib/trametinib) in metastatic melanoma
por: Laino, Antonia, et al.
Publicado: (2018)

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
por: Booth, Andrew E. C., et al.
Publicado: (2020)

MEK + CDK4 a regimen for non-BRAF V6000 melanoma
por: Sosman, Jeff
Publicado: (2015)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
por: Reinhard, Raphael, et al.
Publicado: (2018)

Fibroblasts Influence Metastatic Melanoma Cell Sensitivity to Combined BRAF and MEK Inhibition
por: Morales, Delphine, et al.
Publicado: (2021)

BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
por: Peiffer, Lukas, et al.
Publicado: (2020)

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors
por: Ismail, Rawa K., et al.
Publicado: (2022)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
por: Ascierto, Paolo A., et al.
Publicado: (2023)

Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies
por: Myall, Nathaniel J, et al.
Publicado: (2021)

Effect of Radiation Schedule on Transportation-Related Carbon Emissions: A Case Study in Rectal Cancer
por: Frick, Melissa A., et al.
Publicado: (2023)

Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants
por: Spagnolo, Francesco, et al.
Publicado: (2021)

Lessons from clinical trials on triple combination of immune checkpoint inhibitors and BRAF/MEK inhibitors in BRAF-mutant melanoma
por: Maeda, Takuya, et al.
Publicado: (2023)

RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
por: Lei, Fu Xi, et al.
Publicado: (2018)

BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma
por: Liu, Fen, et al.
Publicado: (2017)

Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study
por: Pópulo, Helena, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_13m316cl442duhjpkucebk3mae